Vantive is investing $1bn towards advancing its kidney care and vital organ support proposition.
The company, which was formerly Baxter’s kidney care unit, becoming Vantive after being spun out as part of a $3.5bn divestment deal with global investment firm Carlyle in 2024, stated that the investment would be allocated over a five-year period and have a particular focus on advancing R&D and manufacturing capacity.
According to Vantive, hastening the course of innovation is critical in order to meet the demand presented by the increasing burden of chronic kidney disease (CKD) end-stage renal disease (ESRD) – which research indicates places an annual healthcare burden on Europe of around $140bn annually.
In addition, there is a pressing need for acute organ support therapy options, with research indicating that 60% of patients in the intensive care unit (ICU) may have acute kidney injury.
Through the development of digitally enabled dialysis and critical care products and services, the company said it aims to power earlier and better-informed clinical decision-making, minimise disruption of care for patients and clinical teams, shift kidney care management from episodic to proactive, and enhance patient-care team connectivity.
In turn, Vantive also plans to build a “stronger” foundation for digital support, with plans to develop existing products including its virtual reality (VR) training on-demand for clinicians using Vantive’s therapies, and its remote patient management platform.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAhead of the European Renal Association (ERA) conference where further details are set to be announced, Vantive CEO Chris Toth said the funding underscored its commitment to “shaping the future of kidney care and vital organ support”.
“Better outcomes are possible when care is more accessible, more intuitive, and more connected to the needs of patients as well as the realities of the modern healthcare ecosystem.
“That’s why we are focused on transforming where and how therapy is delivered – from life-saving critical care for patients in a hospital, to life-sustaining dialysis for patients at home.”
CKD is a metabolic disorder related to conditions such as diabetes, for Glucagon-like peptide-1 receptor agonists (GLP-1Rs) have shown promise. Due to their potentially wider therapeutic benefits, GLP-1R could potentially transform treatment paradigms of multiple chronic diseases, as per GlobalData analysis.
